Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 162

The DOI matches its Crossref record.

Overexpression of the HER-2/ neu Oncogene in Pancreatic Adenocarcinoma

Safran, Howard, Steinhoff, Margaret, Mangray, Shamlal, Rathore, Ritesh, King, Thomas Charles, Chai, Li, Berzein, Katya, Moore, Todd, Iannitti, David, Reiss, Philip, Pasquariello, Terese, Akerman, Paul, Quirk, Daniel, Mass, Robert, Goldstein, Lisa, Tantravahi, Umadevi·2001·American Journal of Clinical Oncology

Abstract

Novel systemic treatments are needed in pancreatic cancer. The authors sought to establish the frequency of overexpression of the HER-2/neu oncogene in patients with pancreatic adenocarcinoma to determine the potential role of trastuzumab (Herceptin) as a therapeutic agent in this disease. Tumor specimens from patients with pancreatic adenocarcinoma were analyzed by staining for p185HER2 protein using the DAKO immunohistochemical assay. Patients with and without HER-2/neu overexpression by immunohistochemistry were compared with respect to clinical and pathologic characteristics. HER-2/neu gene amplification was also evaluated by fluorescence in situ hybridization (FISH). Thirty-two of 154 patients (21%) had pancreatic adenocarcinoma that demonstrated HER-2/neu overexpression by immunohistochemistry. At initial diagnosis, 16% of resectable cancers, 17% of locally advanced cancers, and 26% of metastatic cancers were determined to have HER-2/neu overexpression. Three of 11 (27%) patients with HER-2/neu overexpression by immunohistochemistry had gene amplification by FISH. HER-2/neu overexpression occurs in a subset of pancreatic cancer. Evaluation of the efficacy of trastuzumab for patients with pancreatic cancer who overexpress HER-2/neu appears indicated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00000421-200110000-00016

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 162

Metadata

Authors
Safran, H., Steinhoff, M., Mangray, S., Rathore, R., King, T. C., Chai, L., Berzein, K., Moore, T., Iannitti, D., Reiss, P., Pasquariello, T., Akerman, P., Quirk, D., Mass, R., Goldstein, L., & Tantravahi, U.
Venue
American Journal of Clinical Oncology
Published
2001-10
Volume
24
Issue
5
Pages
496-499
ISSN
0277-3732 (ISSN-L)
OpenAlex
W2030753600
Cited by
162
References
0
FWCI
3.53
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Overexpression of the HER-2/ neu Oncogene in Pancreatic Adenocarcinoma. https://app.cochat.ai/papers/10.1097/00000421-200110000-00016
The paper
Safran, H., Steinhoff, M., Mangray, S., Rathore, R., King, T. C., Chai, L., Berzein, K., Moore, T., Iannitti, D., Reiss, P., Pasquariello, T., Akerman, P., Quirk, D., Mass, R., Goldstein, L., & Tantravahi, U. (2001). Overexpression of the HER-2/ neu Oncogene in Pancreatic Adenocarcinoma. American Journal of Clinical Oncology. https://doi.org/10.1097/00000421-200110000-00016

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.